The dose of S63845 plus venetoclax needed for sustained remission is toxic. (A) Graph depicting weight variation posttreatment in SU-DHL-6 xenografts of different treatment groups: vehicle, venetoclax (ven) (100 mg/kg orally 5 times per week), S63845 (25 mg/kg IV 5 times per week), and a combination of venetoclax (100 mg/kg orally 5 times per week) and S63845 (25 mg/kg IV 5 times per week) for 2 weeks (indicated by black line) (n = 5). Weights are represented as means; error bars represent SD. Two-way analysis of variance (ANOVA) was used to determine statistical significance between the first day of treatment and subsequent time points. (B) Histogram depicting weight variation on days 6 and 13 relative to day 0 posttreatment in different treatment groups from panel A. Two-way ANOVA was used to determine statistical significance between the first day of treatment and subsequent time points. (C-F) Analysis of the effect of combination therapy on WBCs (C), RBCs (D), hemoglobin (E), and platelets (F) on day 24 of treatment in mice from treatment groups detailed in panel A (n = 3). Error bars represent SD. One-way ANOVA was used to determine statistical significance relative to vehicle. **P < .01; *P < .05.